This summer in 2012,At the 2012 7th China Pharmaceutical Industry Top 100 Annual Meeting on July 18th,"Medical Economic Daily" will be a colleague who is anxious with the industry for industry innovation,Explore the more direct path of the innovation and competitiveness of the pharmaceutical industry,Let the innovation and competitiveness directly draw "="..,"Medical Economic Daily" will launch the "China Most Innovative Pharmaceutical Company" list,and invite pharmaceutical companies that insist on innovation,The core competitiveness of pharmaceutical innovation will be transformed into the core competitiveness of pharmaceutical companies for borderless communication。
From imitation to creation needs institutional arrangements
"Because the Chinese pharmaceutical industry has been imitated for many years,New drug research and development can be said to have always been weak in the pharmaceutical industry。In recent years,Some companies that have realized the significance of independent innovation and persistent innovation have begun to have a real new drug listing,But facing the unsuitable facilities of the overall market access and the international influence of the Chinese pharmaceutical market。"Deputy Director of the Southern Medical Economics Research Institute of the State Food and Drug Administration、The editor -in -chief of the "Medical Economic News" Tao Jianhong believes: "At the same time,We also have to see the cold reality hidden,That is the overall innovation strength of the pharmaceutical stake betting appMy stake betting appindustry is not strong,This is a constraint on the improvement of industrial concentration。"In recent years,With the rapid development of China's innovative drug market,More and more competitors have poured into this sea,Among them, international pharmaceutical factories and venture capital institutions that compete for the establishment of a R & D center in China。
At the same time,The Chinese government has also begun to attach importance to biomedical innovation,In the "Eleventh Five -Year" and "Twelfth Five -Year" plan,The government provides tens of billions of yuan and supporting industrial policies to support the development of new drugs。With a large number of returnees with mature scientific research and development capabilities, returned to China,The infrastructure development of new drugs has also continuously strengthened。
In 2011, the harvest year of the Chinese pharmaceutical industry was called new medicine creation。In this year,Eric Subbu (Hengyang) developed by Jiangsu Hengrui Pharmaceutical Co., Ltd.、Zhejiang Beida Pharmaceutical Co., Ltd. self -developed small molecule targets anticancer drug hydrochloride (Kamina)、The world's first small molecule therapy rheumatoid arthritis drugs independently developed by Xianmin Pharmaceuticals Aramod (Aidin),and Taskine Pharmaceutical's Cardiovascular Drug Injection for Radio Anticidase,Get a new type of new drug certificate and registration approval。From the original product of the product,The innovation of these drugs is better than the previous new medicine。
According to the statistics of the regulatory authorities,In 2011, there were dozens of new drugs for clinical applications in my country,This means that in the next few years,New drugs with independent intellectual property rights in my country are expected to be born one after another。National "major new drug creation" special technical chief、Academician Sang Guowei, vice chairman of the Standing Committee of the National People's Congress, also said in public many times: ",my country's new medicine creation will achieve major achievements。"" For a manufacturer that has obtained a new drug certificate,The biggest confusion is the market conversion of new drugs。Ren Jin Sheng, chairman of Xianyin Pharmaceutical, said,Tendering、admission、Medical Insurance has stake sports betting appMy stake betting appbecome the three major difficulties for innovative drugs to realize market transformation。Enterprises are the views of R & D main body.,Only make innovative drugs more convenient to enter the market,Enterprises can have enough enthusiasm to engage in research and development innovation,China's Pharmaceutical Industry can keep up with the world's pace,Really compete with multinational pharmaceutical companies。
"The pharmaceutical industry is a technical dense industry in the world,Now whether it is standard or clinical requirements,Gradually in line with international。"Xiao Wei, Chairman of Kangyuan Pharmaceutical, pointed out,Pay huge for innovative pharmaceutical companies,Related domestic policies should support domestic innovative drugs,Make it a reasonable return。
Another,At present, it takes at least 2 years to enter the local medical insurance catalog after a innovative drug is listed in my country,If you want to enter the category of medical insurance category,It takes at least 5 years。This,Chairman Yan Xijun, chairman of Tiansi said: "A innovative drug takes 10-15 years to get the birth certificate,Can't enter the medical insurance directory,Can't enter the basic drug directory normally,Who will come to innovate? "
How to make innovation = competitiveness
Quickly transform the increasingly mature innovation of the Chinese pharmaceutical industry into international competitiveness,This is an urgent problem that the current medical community needs to pay attention to and in -depth exchanges。
Tao Jianhong said,The list of "China's Most Innovative Pharmaceutical Company" was set up at this year's top 100 annual meeting,I hope,Make more in -depth analysis and research on independent innovation in the Chinese pharmaceutical industry,Follow the industrial common problems they face,Condensing the real and constructive industrial consensus,Jointly promote the industry to move forward。
Tao Jianhong pointed out,The world is accelerating integration,Chinese pharmaceutical companies have gradually strengthened their cooperation with the world from closed doors to start research and development,We should have the courage to "lunch with the strong". If you invest in cooperation,The core research of innovative drugs can also be obtained in China,This is a win -win complement。This kind of independent innovation led by the enterprise、Stake Sports Bettingstake sports betting appR & D leading joint venture research and development model,Created a new international drug research and development cooperation dimension。Now the world's multi -centered clinical clinical has also shifted to China,On the one hand, the potential of the listing of new Chinese medicines is far greater than Europe and the United States,On the other hand,Through Chinese research, the applicability of the Asian people,It can speed up the process of listing of new drugs。
Yan Xijun also said,In the historical revival cause of the Chinese nation,Chinese companies have the same era mission,The mission of contemporary enterprises is how to improve international competitiveness,Become a world -class。
From Yan Xijun's view,For 30 years of reform and opening up,Processing through the camera、Technology introduction、Technology transfer,Introduction to digestion and absorption and then innovate,Exogenous scientific and technological achievements have promoted the rapid development of modern Chinese industry,significantly improved China's economic status and technology strength,Created the foundation for Chinese companies to move towards the world。Taking traditional Chinese medicine as an example to see development,To reach the world's first -class,It must have the strategy of "three steps" in its internationalization。1. Go out: Go out of the country。2. Go in: Technical goes to the world。3. Go up: the product is high -end。To make the new drugs in China's pharmaceutical industry connect with the standards of the international market、Language -free barrier、Products have affinity、Consumers have a sense of trust,must be systemic、Industrialization system promotion。
A senior vice president of Xianyou Pharmaceutical said,Enterprises with innovative power must embed the innovation consciousness into the genes of the enterprise,There must be a unique and effective innovation mode,Adhere to independent research and development; there must be an industry -leading innovation research and development mechanism,Continuous investment,Effective transformation; it is necessary to achieve significant innovative research and development results,Have a complete product echelon。
The reporter learned in the interview,For the new Chinese medicine R & D,The current most attractive is not only the funds of the international fund,Also providing overseas synchronous experiment My stake betting appstake betting appopportunities。For example, Shanghai Asia brought the new drug of Shenzhen micro -core into the United States for clinical trials,Different standards have different standards due to the US FDA and China SFDA,So that Chinese developers can synchronize results into the international market。After the experiment to copy in the United States is progressing,The R & D team is expected to get the "milestone" type income,If the new drug is launched,R & D can also be divided into the sales income of new drugs。
Tao Jianhong thinks,This means,In the process of transforming industrial innovation into international competitiveness,Not only the domestic new drug market conversion mechanism is an important basic guarantee,The listing of products in major pharmaceutical markets such as products in the United States and Europe is also very important,This also puts forward requirements for the overall improvement of the domestic pharmaceutical market。
